Furthermore, they demonstrated that TMEM16A knockdown reduced the autocrine secretion of EGFR ligands, EGF and TGF-α in breast cancer cells, suggesting that TMEM16A can activate EGFR signaling by increasing autocrine secretion of EGFR-ligands [42]. The gene discussed is ANO1; the disease is breast cancer.